Efanesoctocog alfa: Treatment starts when the patient completes the parent study and continues until efanesoctocog alfa is commercially available in each patient's respective country, or until March 2027, whichever comes first.
Study summary
This is a multinational, prospective, open-label, roll-over study in patients with haemophilia A, ≥6 years of age, who have completed participation in any of the parental studies with efanesoctocog alfa; XTEND-ed study (LTS16294), FREEDOM study (Sobi.BIVV001-001), PK comparison study (Sobi.BIVV001-003) or SHINE study (Sobi.BIVV001-004). The aim of the study is to provide patients with continuous benefit from efanesoctocog alfa treatment and to further continue clinical monitoring for safety and efficacy until efanesoctocog alfa is commercially available in each patient's respective country (or until March 2027, whichever comes first).
The study starts with the Baseline Visit, which will be done in connection to the end of treatment at the EoT/EoS visit (or equivalent) in the respective parent study. Subsequent study visits (on site or phone call) will be done approximately every 13 weeks until End of Treatment. An End of Study safety phone call will be done 14 (+7) days after the End of Treatment Visit.
Eligibility
Sex
MALE
Min age
6 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Capable of giving signed informed consent. Parents or legally designated representatives' consent is required for patients who are below 18 years of age or unable to give consent. Patients who are below 18 years of age may provide assent in addition to the parents'/legally designated representatives' consent, if appropriate.
* Must have completed one of the required parent studies: Sobi.BIVV001-001, Sobi.BIVV001-003, LTS16294, or Sobi.BIVV001-004, and be receiving a clinical benefit from the efanesoctocog alfa treatment, as judged by the Investigator.
* Willingness and ability of patient or their parent or legally designated representative to complete training in the use of the study patient diary and to complete the diary throughout the study.
Exclusion Criteria:
* Positive inhibitor result, defined as ≥0.6 Bethesda units (BU)/mL, present at the Baseline Visit.
* Ongoing or planned participation in any interventional clinical study at the Baseline Visit.
* Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or patients potentially at risk of noncompliance to study procedures.
Primary outcome measure(s)
Number of injections to treat a bleeding episode — From enrollment and up to 52 weeks
Total dose to treat a bleeding episode — From enrollment and up to 52 weeks
Adverse events (AEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs) — From enrollment and up to 52 weeks Number of participants with occurrence of AEs, SAEs, and AESIs
Annualized bleeding rate (ABR) for treated bleeding episodes — From enrollment and up to 52 weeks ABR for treated bleeding episodes during prophylactic treatment.
Annualized bleeding rate (ABR) for treated bleeding episodes by type of bleed — From enrollment and up to 52 weeks ABR for treated bleeding episodes during prophylactic treatment by type of bleed.
Annualized bleeding rate (ABR) for treated bleeding episodes by location of bleed — From enrollment and up to 52 weeks ABR for treated bleeding episodes during prophylactic treatment by location of bleed.
Annualized bleeding rate (ABR) for all bleeding episodes — From enrollment and up to 52 weeks ABR for all bleeding episodes (including untreated bleeding episodes, excluding surgery bleeds) during prophylactic treatment.
Annualized bleeding rate (ABR) for all bleeding episodes by type of bleed — From enrollment and up to 52 weeks ABR for all bleeding episodes (including untreated bleeding episodes, excluding surgery bleeds) during prophylactic treatment, by type of bleed.
Annualized bleeding rate (ABR) for all bleeding episodes by location of bleed — From enrollment and up to 52 weeks ABR for all bleeding episodes (including untreated bleeding episodes, excluding surgery bleeds) during prophylactic treatment, by location of bleed.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
